Black Diamond Therapeutics, Inc., established in 2014 and headquartered in Cambridge, Massachusetts, specializes in precision oncology medicine. The company discovers and develops small molecule therapies that are tumor-agnostic, meaning they target specific genetic mutations across various cancer types rather than being limited to a single cancer indication. Its lead product candidate, BDTX-189, inhibits non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR). The company's Mutation-Allostery-Pharmacology platform enables it to target undrugged mutations in patients with genetically defined cancers, offering new treatment options where few exist. Black Diamond Therapeutics is also advancing early-stage pipeline programs targeting allosteric mutations in other cancer-related kinases.
Launchpad Therapeutics is an antibody-focused precision oncology company that specializes in developing early mutant-selective antibodies to enhance cancer therapies. Utilizing artificial intelligence-driven programs, the company aims to create novel monoclonal antibodies, facilitating drug design, development, and testing for research purposes. This innovative approach provides medical professionals with new alternatives for cancer treatment, addressing the complexities of the disease through targeted therapeutic strategies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.